Cancer drug shows promise for recurrent gynecologic tumors
NCT ID NCT06865677
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 24 times
Summary
This study tested a drug called sacituzumab govitecan in people whose ovarian, endometrial, or cervical cancer returned after at least two rounds of standard treatment. Participants received the drug through an IV on days 1 and 8 of each 21-day cycle. The goal was to see if the drug could shrink or eliminate tumors. The study was terminated early after enrolling only 2 participants, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT PLATINUM RESISTANT EPITHELIAL OVARIAN CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.